Gliosarcoma clinical trials at UCLA
2 in progress, 1 open to eligible people
ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
open to eligible people ages 18 years and up
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Los Angeles, California and other locations
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
Sorry, in progress, not accepting new patients
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas. Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells.
Los Angeles, California and other locations
Last updated: